LONGi and KENO enter partnership to bring 300MW high efficiency solar modules for customers in Poland

LONGi and KENO enter partnership to bring 300MW high-efficiency solar modules for customers in Poland

Condividi: 25 gennaio 2021 – XI’AN, China, Jan. 25, 2021 /PRNewswire/ — LONGi, one of the world leading PV manufacturers, and KENO, one of the largest distributors located in Gliwice, Poland, recently signed an agreement to ensure supplies at the level of 300MW in the coming year. This is the next step in developing long-term relationships and increasing cooperation between the manufacturer and the distributor.
The cooperation between LONGi Solar and KENO has been developing since the beginleggi di più…

Ynsect On Track To Enter The Human Food Market With A Positive Assessment From The EFSA

Ÿnsect On Track To Enter The Human Food Market With A Positive Assessment From The EFSA

Condividi: 14 gennaio 2021 –  The European Food Safety Authority (EFSA) deems mealworms safe for human consumption –
PARIS, Jan. 13, 2021 /PRNewswire/ — Getting the provisional green light from the EFSA[1] is a major step forward for the industry. It should pave the way for future approvals, particularly on human consumption of defatted insect protein, which represents the largest human food market segment in terms of value and volumes, especially in sports and health nutrition.
On Januarleggi di più…

Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC 203

Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203

Condividi: 07 gennaio 2021 SHANGHAI and TAIPEI, Jan. 7, 2021 /PRNewswire/ — Hongkong Winhealth Pharma Group (Winhealth Pharma) and Taiwan TWi Biotechnology, Inc. (TWiB) announced strategic partnership granting Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB), bullous pemphigoid and other skin diseases.
The prevalence of EB in the United States is aboleggi di più…

WinHealth and Immedica enter agreement giving Winhealth rights to Ravicti® in China and several other Asia Pacific countries

WinHealth and Immedica enter agreement giving Winhealth rights to Ravicti® in China and several other Asia-Pacific countries

Condividi: 31 dicembre 2020 STOCKHOLM and HANGZHOU, China, Dec. 31, 2020 /PRNewswire/ — Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti® (glycerol phenylbutyrate), in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand.
Ravicti® is in Europe and North America indicated for treatmeleggi di più…

Peijia Medical and HighLife Enter Into License and Technology Transfer Agreement for Transeptal Mitral Valve Replacement in Greater China

Peijia Medical and HighLife Enter Into License and Technology Transfer Agreement for Transeptal Mitral Valve Replacement in Greater China

Condividi: 21 dicembre 2020 Collaboration Strengthens Peijia’s Position for Competing in a Largely Untapped Market and Supports Global Expansion of HighLife’s Technology
SUZHOU, China and PARIS, Dec. 21, 2020 /PRNewswire/ — Peijia Medical Ltd (HK Stock Code: 09996) and HighLife SAS, a Paris-based medical device company, focused on the development of a unique transeptal mitral valve replacement (“TMVR”) system to treat patients suffering from mitral regurgitation, announced that they haveleggi di più…